Antibacterial Soap Decline Likely In Reaction To Triclosan Debate
This article was originally published in The Tan Sheet
Executive Summary
FDA’s recent proposal to amend the OTC antiseptic drug product monograph could impact sales of antibacterial soaps, according to analysts from market research firm Kline & Co. Firms will “likely choose the path of least resistance” and replace controversial ingredient triclosan, they predict.
You may also be interested in...
FDA Says Antiseptics Need Testing Or Face Reformulation, Relabeling
FDA proposes to amend the OTC antiseptic drug product monograph to require more detailed safety and efficacy tests, pointing to mounting data that shows antibacterial wash products could pose health risks and contribute to increase antibacterial resistance.
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
Women’s Voices For The Earth Will Keep After CIR, Salon Worker Safety In 2024
Women’s Voices for the Earth continues to call attention to cosmetic ingredients’ potential health impacts on users including salon workers, while pushing the Cosmetic Ingredient Review to consider a wider variety of safety information in its assessment work.